Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2019 · New England Journal of Medicine · 2,755 citations
https://doi.org/10.1056/nejmoa1910231
S
Sang‐We Kim
Ulsan College(KR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
369
Papers
21.5K
Citations
57
h-index
172
i10-index
Sang‐We Kim is an academic researcher from Ulsan College. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 57, co-authored 314 publications.
ORCID: 0000-0003-1065-8095Papers by this author
worksDurvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · The Lancet · 2,108 citations
https://doi.org/10.1016/s0140-6736(19)32222-6
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017 · Journal of Clinical Oncology · 580 citations
https://doi.org/10.1200/jco.2016.71.5904
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
2023 · New England Journal of Medicine · 546 citations
https://doi.org/10.1056/nejmoa2306434
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
2023 · New England Journal of Medicine · 301 citations
https://doi.org/10.1056/nejmoa2306441
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat